REG - Solvonis Therapeutic - Appointment of Prof. David Nutt as CSO

Solvonis TherapeuticsAnnouncement

03/06/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250603:nRSC1028La&default-theme=true

RNS Number : 1028L  Solvonis Therapeutics PLC  03 June 2025

3 June 2025
Solvonis Therapeutics plc

("Solvonis" or the "Company")

Appointment of Professor David Nutt as Chief Scientific Officer

 

Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders,
is pleased to announce that Professor David Nutt, who has served as Senior
Scientific Advisor to the Company since July 2024, has been appointed to the
Company's management team as Chief Scientific Officer ("CSO") with immediate
effect.

Professor Nutt is one of the world's foremost authorities in brain science and
psychiatric medicine, with a distinguished career spanning more than four
decades. He holds the Edmond J. Safra Chair in Neuropsychopharmacology at
Imperial College London, where he leads the Neuropsychopharmacology Unit
within the Division of Brain Sciences. His research has significantly advanced
the understanding and treatment of central nervous system ("CNS") disorders,
particularly in addiction, depression, anxiety, and other high-burden mental
health conditions.

Professor Nutt has authored over 600 peer-reviewed publications and several
landmark texts on psychiatric illness, brain chemistry and CNS drug
development. His work has played a pivotal role in translating neuroscience
into effective clinical interventions. Professor Nutt is a Fellow of the Royal
College of Physicians, the Royal College of Psychiatrists and the Academy of
Medical Sciences and has held senior advisory roles with leading UK and
European medical research institutions.

Professor David Nutt, CSO of Solvonis, commented: "It's a privilege to take on
this expanded role at Solvonis at such a pivotal stage in the Company's
growth. Solvonis is distinguished by its unwavering commitment to rigorous
neuroscience, translational innovation, and clinically grounded development -
all of which align closely with my own scientific philosophy. The pipeline
reflects both ambition and focus, with the potential to deliver transformative
treatments for brain disorders that continue to impose an immense personal and
societal burden. I look forward to helping accelerate the development of
therapies that are not only scientifically robust, but capable of making a
real difference in patients' lives at scale.""

As CSO, Professor Nutt will lead the scientific strategy and clinical
development of Solvonis' expanding pipeline, including:

·    SVN-001 - a Phase 3-stage, proprietary combination of intravenous
ketamine and relapse-prevention cognitive behavioural therapy ("CBT") for
severe Alcohol Use Disorder ("AUD"), currently being evaluated across eight
NHS Trusts in the UK. The trial is co-funded by the Medical Research Council
("MRC"), the National Institute for Health and Care Research ("NIHR") and
Solvonis.

 

·    SVN-002 - a patent-pending sublingual/buccal esketamine formulation,
paired with therapy, targeting moderate to severe AUD for the US market. The
programme is in Phase 2b planning under the FDA 505(b)(2) regulatory pathway.

 

·    SVN-SDN-14 - a preclinical-stage programme focused on multi-receptor
modulation (serotonin, dopamine, noradrenaline) to promote pro-social
behaviour and improve safety relative to existing investigational therapies
for trauma related mental health disorders, such as Post-Traumatic Stress
Disorder ("PTSD").

 

·    Solvonis' proprietary CNS compound library, comprising multiple
patented chemical series that have completed hit-to-lead progression.
Professor Nutt will oversee scientific direction, asset prioritisation, and
translational development across the early-stage pipeline.

Professor Nutt's scientific leadership will be instrumental in shaping
translational strategy, regulatory engagement, and clinical execution across
the Company's portfolio.

This non-board appointment reinforces Solvonis' commitment to world-class
neuroscience and to delivering innovation in areas of urgent, unmet clinical
need.

Anthony Tennyson, CEO of Solvonis, commented: "David is one of the most
accomplished neuroscientists of his generation. His contributions to our
understanding of brain chemistry and psychiatric illness are unmatched, and
his leadership will be central to advancing Solvonis' pipeline of novel
therapeutics for addiction and mental health disorders.  We are delighted
that David has agreed to become Solvonis' CSO."

 

Enquiries:

Solvonis Therapeutics plc

Anthony Tennyson, CEO & Executive Director

anthony@solvonis.com

Allenby Capital Limited (Financial Adviser and Joint Broker)

Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)

Guy McDougall (Sales & Corporate Broking)

+44 (0) 20 3328 5656

Singer Capital Markets (Joint Broker)

Phil Davies

+44 (0) 20 7496 3000

About Solvonis Therapeutics plc

Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical
company developing novel medicines for addiction and mental health disorders.
Headquartered in London and listed on the main market of the London Stock
Exchange, Solvonis is advancing a differentiated pipeline of repurposed and
novel compounds that target high-burden neuropsychiatric conditions with
significant unmet need.

The company's lead programs address Alcohol Use Disorder (AUD) and
Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million
people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in
Phase 3 trials for severe AUD in Europe and the UK. SVN-002 is preparing for a
Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a
preclinical PTSD program leveraging novel serotonin-dopamine modulators
designed to enhance pro-social behaviour and long-term outcomes.

With a capital-efficient model, dual development strategy, and near-term
partnering opportunities, Solvonis is positioned to generate value through
innovation in neuropsychiatry.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDUPUQAQUPAGQP